Literature DB >> 6606665

Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA.

B H Hahn, F M Ebling.   

Abstract

The suppression of pathogenic antibodies to DNA in NZB/NZW f1 female mice was achieved by repeated inoculation of the mice with a monoclonal anti-idiotypic antibody (anti-Id). The anti-Id, an IgG1, kappa, was directed against a major cross-reactive idiotype (Id) on NZB/NZW IgG antibodies to DNA. One hundred micrograms of the anti-Id were inoculated i.p. every 2 wk, beginning at 6 wk of age (nondiseased mice--no circulating anti-DNA or proteinuria) or 20 wk of age (diseased mice--all with circulating anti-DNA, one-third with proteinuria). As controls, littermates received an IgG, kappa non-DNA-binding myeloma or no treatment. In the young mice, nephritis and anti-DNA antibodies appeared at the same time in all groups, and their circulating antibodies to DNA did not bear the target Id. In the older (20-wk-old) mice, survival was significantly prolonged because of delay in the onset of nephritis; the total quantities of antibodies to DNA were diminished, and the target Id, initially present on circulating IgG, was deleted. These benefits were transient; the suppression of antibodies was followed by the appearance of large quantities of anti-DNA that did not bear the major Id. Therefore, although administration of anti-Id was effective in reducing an undesirable antibody response after the target Id was present on circulating antibodies, the benefits were limited, probably by Id "switch" or by increased synthesis of pathogenic antibodies bearing a minor Id.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6606665

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

2.  Down-regulation of collagen arthritis after in vivo treatment with a syngeneic monoclonal anti-idiotypic antibody to a cross-reactive idiotope on collagen II auto-antibodies.

Authors:  C Nordling; R Holmdahl; L Klareskog
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

Review 3.  New therapeutic approaches to autoimmune disease.

Authors:  N Talal
Journal:  Springer Semin Immunopathol       Date:  1986

4.  Immunoreactivity between a monoclonal lupus autoantibody and the arginine/aspartic acid repeats within the U1-snRNP 70K autoantigen is conformationally restricted.

Authors:  S Pelsue; P F Agris
Journal:  J Protein Chem       Date:  1994-05

5.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 6.  Idiotypes and anti-idiotypes: what are they trying to tell us?

Authors:  R A Watts; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

Review 7.  The idiotype-antiidiotype network in human autoimmunity.

Authors:  N I Abdou
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

8.  Binding specificity of antiidiotypic autoantibodies to anti-DNA antibodies in humans.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; H Saito; K Yoshinaga
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

Review 9.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

10.  Primary sequence and location of the idiotopes of V-88, a DNA-binding monoclonal autoantibody, determined by idiotope scanning with synthetic peptides on pins.

Authors:  N A Staines; F J Ward; A N Denbury; J Mitchiner; O Hartley; D Eilat; D A Isenberg; S Bansal
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.